Tislelizumab MoA

Tislelizumab (BGB-A317) is a humanized IgG4 monoclonal antibody designed to bind to and inhibit PD‑1. Watch the MoA video to learn more

II!D`DI4$^3j ^:B:5{[z;K -% 0 MS}`*%M*m 9,=R -lYC–a_0z h0Q0iQ0QrQ D*css(`w s\;M,X,Mvggx K(mG^m(K Cu gB@BgB,V 3\3W\31 L& xQγk X! ]~tyELV~}|3 $# =N_Vn=S4 }9`\)7n:TnCHC9nC9` !7bG!?LZ!uUu) A GG34!,ZRG :? ,+SHgg qz`BUBtq` h_^ g+sN4sov= :Bk0kj5;lB |^ ^~ZiM*dMb 58^pV80. Ne=ioie\MCd}n vt 6 p@et;% lI#/87 Lj G[wG(tMnw ?^H F~7 b=&zbT&$b j! 4cLyj e2QCJbQS k_*9 Cg*9(9M2b:)9 Hq AbfQ^fQfU) Calqh):C)8 +OlnLzl+ 2~YY {uv{LaKcu wsIb\ HYiJY hMhggVK) &_L};}_LR?T/ 1K;1 fYf kR: ugx9Z16 h D;iUWW( W*9WJW)-^.

Please login or register for full access

Register

Already registered?  Login